Disease-modifying treatment of Parkinson’s disease by phytochemicals: targeting multiple pathogenic factors

被引:0
|
作者
Makoto Naoi
Wakako Maruyama
Masayo Shamoto-Nagai
机构
[1] Aichi Gakuin University,Department of Health and Nutrition, Faculty of Psychological and Physical Science
来源
关键词
Parkinson’s disease; Phytochemicals; Neuroprotection; Mitochondria; α-Synuclein;
D O I
暂无
中图分类号
学科分类号
摘要
Parkinson’s disease is characterized by typical motor symptoms, loss of dopamine neurons in the substantia nigra, and accumulation of Lewy body composed of mutated α-synuclein. However, now it is considered as a generalized disease with multiple pathological features. Present available treatments can ameliorate symptoms at least for a while, but only a few therapies could delay progressive neurodegeneration of dopamine neurons. Lewy body accumulates in peripheral tissues many years before motor dysfunction becomes manifest, suggesting that disease-modifying therapy should start earlier during the premotor stage. Long-termed regulation of lifestyle, diet and supplement of nutraceuticals may be possible ways for the disease-modification. Diet can reduce the incidence of Parkinson’s disease and phytochemicals, major bioactive ingredients of herbs and plant food, modulate multiple pathogenic factors and exert neuroprotective effects in preclinical studies. This review presents mechanisms underlying neuroprotection of phytochemicals against neuronal cell death and α-synuclein toxicity in Parkinson’s disease. Phytochemicals are antioxidants, maintain mitochondrial function and homeostasis, prevent intrinsic apoptosis and neuroinflammation, activate cellular signal pathways to induce anti-apoptotic and pro-survival genes, such as Bcl-2 protein family and neurotrophic factors, and promote cleavage of damaged mitochondria and α-synuclein aggregates. Phytochemicals prevent α-synuclein oligomerization and aggregation, and dissolve preformed α-synuclein aggregates. Novel neuroprotective agents are expected to develop based on the scaffold of phytochemicals permeable across the blood–brain–barrier, to increase the bioavailability, ameliorate brain dysfunction and prevent neurodegeneration.
引用
收藏
页码:737 / 753
页数:16
相关论文
共 50 条
  • [21] miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson's disease
    Suvarna, Vasanti
    Deshmukh, Kajal
    Murahari, Manikanta
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [22] GM1 Ganglioside as a Disease-Modifying Therapeutic for Parkinson's Disease: A Multi-Functional Glycosphingolipid That Targets Multiple Parkinson's Disease-Relevant Pathogenic Mechanisms
    Schneider, Jay S. S.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (11)
  • [23] Disease-Modifying Treatment in Progressive Multiple Sclerosis
    Ciotti, John Robert
    Cross, Anne Haney
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2018, 20 (05)
  • [24] Immunotherapy for Parkinson's Disease and Alzheimer's Disease: A Promising Disease-Modifying Therapy
    Mahboob, Anns
    Ali, Hasan
    Alnaimi, Aljazi
    Yousef, Mahmoud
    Rob, Mlaak
    Al-Muhannadi, Nawaf Ahmad
    Senevirathne, Degiri Kalana Lasanga
    Chaari, Ali
    CELLS, 2024, 13 (18)
  • [25] Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease
    Mestre, Tiago A.
    Macklin, Eric A.
    Ascherio, Alberto
    Ferreira, Joaquim J.
    Lang, Anthony E.
    Schwarzschild, Michael A.
    MOVEMENT DISORDERS, 2021, 36 (08) : 1964 - 1967
  • [26] Disease-Modifying Treatment in Progressive Multiple Sclerosis
    John Robert Ciotti
    Anne Haney Cross
    Current Treatment Options in Neurology, 2018, 20
  • [27] Current Disease-Modifying Treatment of Multiple Sclerosis
    Derwenskus, Joy
    MOUNT SINAI JOURNAL OF MEDICINE, 2011, 78 (02): : 161 - 175
  • [28] The search for disease-modifying treatment for Alzheimer's disease
    Aisen, PS
    Davis, KL
    NEUROLOGY, 1997, 48 (05) : S35 - S41
  • [29] Delivering a disease-modifying treatment for Huntington's disease
    Godinho, Bruno M. D. C.
    Malhotra, Meenakshi
    O'Driscoll, Caitriona M.
    Cryan, John F.
    DRUG DISCOVERY TODAY, 2015, 20 (01) : 50 - 64
  • [30] Disease-modifying treatment approaches for Alzheimer's disease
    Froelich, Lutz
    Hausner, Lucrezia
    NERVENARZT, 2021, 92 (12): : 1239 - 1248